RhumbLine Advisers
LTRN icon

RhumbLine Advisers’s Lantern Pharma LTRN Stock Holding History

RhumbLine Advisers’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-208
Closed -$971 – 4275
2024
Q2 		$971 Sell
208
-20
-9% -$120 ﹤0.01% 4245
2024
Q1 		$2.01K Hold
228
– – ﹤0.01% 4090
2023
Q4 		$975 Hold
228
– – ﹤0.01% 4157
2023
Q3 		$777 Hold
228
– – ﹤0.01% 4206
2023
Q2 		$1.28K Buy
+228
New +$1.18K ﹤0.01% 4261

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

RhumbLine Advisers's LTRN Position: Q3 2024 in Review

RhumbLine Advisers sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 208 shares — an estimated $971 sold.

RhumbLine Advisers first reported a position in LTRN in Q2 2023 and held it in 5 quarters. The position peaked at $2.01K in Q1 2024. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

  • RhumbLine Advisers reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 208 Lantern Pharma shares in Q3 2024, an estimated $971.
  • RhumbLine Advisers first reported a position in Lantern Pharma in Q2 2023 and held it in 5 quarters.
  • RhumbLine Advisers's Lantern Pharma position peaked at $2.01K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.